Baron and Budd Examining Internal Company Memo Connected to the GranuFlo Lawsuit

  Baron and Budd Examining Internal Company Memo Connected to the GranuFlo
  Lawsuit

 An internal company memo sent by Fresenius Medical Care allegedly shows that
                   Fresenius was aware of GranuFlo's risks

Business Wire

DALLAS -- July 30, 2013

Baron and Budd, a nationally recognized plaintiffs’ law firm, is handling
cases related to the GranuFlo lawsuit. Currently, Baron and Budd is examining
the internal company memo sent out by Fresenius Medical Care on November 4,
2011. This memo may help to show that Fresenius Medical Care allegedly
understood the dangers associated with their popular dialysis product and
chose to not alert their entire consumer base.

Fresenius Medical Care is the leading producer of products and services for
kidney dialysis and over one-third of the more than 400,000 Americans who
undergo dialysis treatments each year go to Fresenius clinics for their
dialysis treatment. Unfortunately, the memo reveals a potential consequence of
GranuFlo use: that dialysis patients who are given GranuFlo may develop excess
levels of bicarbonate in their blood, leading to a four to six times increase
in the likelihood of cardiac arrest.Additionally, out of the many dialysis
products on the market, GranuFlo, along with its sister drug NaturaLyte, is
particularly prone to produce excess levels of bicarbonate.

“Patients undergoing dialysis are already struggling with health issues,” said
Russell Budd, president and managing shareholder at Baron and Budd. “They
shouldn't have to worry even more about their dialysis treatments."

The internal company memo allegedly shows that Fresenius Medical Center was
aware of the increased levels of bicarbonate risk associated with GranuFlo.
Had Fresenius Medical Center followed the internal company memo with a wide
scale alert to the entire patient list, including patients who used the
GranuFlo product at non-Fresenius dialysis centers, than dialysis patients
might have avoided serious health complications.

If you or someone you know has received GranuFlo treatments and suffered
serious health issues as a result, contact our GranuFlo lawyers today at
1.866.844.4556 or email us at info@baronbudd.com. For more information about
GranuFlo lawyers and Baron and Budd, visit Baron and Budd’s website
here:http://baronandbudd.com/areas-of-practice/pharmaceuticals/granuflo-lawyer/.

For more than 35 years, Baron and Budd lawyers have been protecting the rights
of people who have been harmed by negligent companies. The firm has an
established track record of success. Recently, Baron and Budd lawyers were
involved in litigation surrounding the diabetes drug Avandia. Baron and Budd
represented more than 7,000 patients harmed by Avandia use, and currently
represents numerous states in lawsuits against Avandia manufacturer
GlaxoSmithKline. In the 1990s, the firm was closely involved in litigation
surrounding the once popular diet drug Fen-Phen. The resulting global
settlement was valued at over $1.275 billion.

In addition to GranuFlo,Baron and Budd is handling lawsuits related to harms
caused by Lipitor, Actos and Transvaginal Mesh.

About Baron & Budd, P.C.

The law firm of Baron & Budd, P.C., with offices in Dallas, Baton Rouge,
Austin and Los Angeles, is a nationally recognized law firm with a 35-year
history of "Protecting What's Right" for people, communities and businesses
harmed by negligence. Baron & Budd's size and resources enable the firm to
take on large and complex cases. The firm represents individuals, governmental
and business entities in areas as diverse as water contamination, Gulf oil
spill, Qui Tam, California Proposition 65 violations, dangerous medications
and medical devices, Chinese drywall, insurance claims, consumer fraud,
securities fraud and asbestos-related illnesses such as mesothelioma.

Contact:

Baron & Budd
Susan Knape, 214-629-0596
susan@susanknape.com
or
Amanda Billo, 214-991-1051
abillo@baronbudd.com